STAR-LLD

A Protocol to Assess the Safety, Efficacy, and Pharmacokinetics of Continuous Subcutaneous Administration of Low-dose Lenalidomide (STAR-LLD) for the Treatment of Multiple Myeloma (MM)

Published Results

Starton Therapeutics Presents Positive Data from Phase 1b Study Evaluating STAR-LLD for the Treatment of Relapsed/Refractory Multiple Myeloma

Six relapsed/refractory MM patients were enrolled from two U.S. community-based investigational sites in the Phase 1b study. Median age was 73, male to female ratio 1/1, Caucasian 100%, and median lines of previous therapy were 2 (range 1-7). Two patients were refractory and four were relapsed to their prior treatment. Four patients were previously exposed to lenalidomide, one of which was discontinued from a prior regimen because of severe fatigue, and all six had received prior bortezomib. Patients received 3-12 cycles of study therapy.

  • No patients experienced drug-related anemia, neutropenia, leukopenia, or thrombocytopenia greater than grade 2 in up to 12 cycles of therapy.
  • Non-hematologic toxicities did not exceed Grade 2
  • The PK/PD data minimized Cmax and lowered AUC while achieving biologically active doses and reducing toxicity
    • STAR-LLD pharmacokinetics produced median steady-state blood levels (Cmax) of 39 ng/mL (N=6) and were above the minimum target of 25 ng/mL.
  • All six patients receiving STAR-LLD achieved an objective response (1 CR and 5 PRs); one patient who achieved a partial response experienced a Grade 2 skin reaction during cycle 3 and withdrew from the study
  • Continuous treatment with STAR-LLD does not appear to significantly increase immune checkpoints associated with T cell exhaustion
  • Five patients are continuing treatment per protocol with a median PFS of > 10 months
3 months agoRead more

Resources

(888) 828-2206

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print this trial to share with your doctor.

We can help answer any questions and connect you (or your patient) with the study team.

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.